RT Journal Article
T1 Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
A1 Diaz, Asuncion
A1 Diez, Mercedes
A1 Bleda, Maria Jose
A1 Aldamiz, Mikel
A1 Camafort, Miguel
A1 Camino, Xabier
A1 Cepeda, Concepcion
A1 Costa, Asuncion
A1 Ferrero, Oscar
A1 Geijo, Paloma
A1 Iribarren, Jose Antonio
A1 Moreno, Santiago
A1 Moreno, Maria Elena
A1 Labarga, Pablo
A1 Pinilla, Javier
A1 Portu, Joseba
A1 Pulido, Federico
A1 Rosa, Carmen
A1 Santamaría, Juan Miguel
A1 Telenti, Mauricio
A1 Trapiella, Luis
A1 Trastoy, Monica
A1 Viciana, Pompeyo
K1 Antituberculosos
K1 Infecciones por VIH
K1 Humanos
K1 Cumplimiento de la Medicación
K1 Estudios Prospectivos
K1 España
K1 Resultado del Tratamiento
K1 Adulto
AB BACKGROUNDPrevious studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion.METHODSSubjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI).RESULTSA total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9).CONCLUSIONSA minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.
PB BIOMED CENTRAL LTD
YR 2010
FD 2010-09-14
LK http://hdl.handle.net/10668/1791
UL http://hdl.handle.net/10668/1791
LA en
NO Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, et al. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis. 2010; 10:267
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 6, 2025